NDAINJECTIONINJECTABLE
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 300 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1998.
Drug data last refreshed 2h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 300 (ioversol) is an injectable radiographic contrast agent used to enhance visualization during X-ray and imaging procedures. It works through X-ray contrast activity to improve diagnostic image quality. The drug serves as an essential tool in diagnostic radiology for visualizing vascular and organ structures.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), teams are likely in transition or optimization mode, suggesting smaller, specialized commercial units focused on market defense.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPTIRAY 300 offers experience in mature product management and diagnostic pharmaceutical commercial execution within a stable, well-established market. Career trajectory typically emphasizes market access, hospital relationships, and operational efficiency rather than innovation or launch dynamics.
Brand ManagerField Sales Representative
Worked on OPTIRAY 300 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.